Both in vitro and in vivo experiments were performed to elucidate the relevance of DC-SIGNR-mediated tumor metastasis, and the inhibition of DC-SIGNR activity or of downstream DC-SIGNR-regulated events could be a therapeutic intervention for colon cancer formation. The gene discussed is CLEC4M; the disease is malignant colon neoplasm.